---
title: "Kangxin New Materials: Expected net profit loss of 286 million yuan in 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225007813.md"
description: "Kangxin New Materials announced that it is expected to achieve a net profit attributable to shareholders of the listed company of -286 million yuan for the year 2024, continuing to incur losses compared to the same period last year. It is expected that the net profit attributable to shareholders of the listed company, after deducting non-recurring gains and losses, will be -289 million yuan for the year 2024"
datetime: "2025-01-15T07:36:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225007813.md)
  - [en](https://longbridge.com/en/news/225007813.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225007813.md)
generator: "portal-rs"
---

# Kangxin New Materials: Expected net profit loss of 286 million yuan in 2024

Jin Shi Data reported on January 15th that Kangxin New Materials announced that it expects to achieve a net profit attributable to shareholders of the listed company of -286 million yuan for the year 2024, continuing to incur losses compared to the same period last year. It is expected that the net profit attributable to shareholders of the listed company, after deducting non-recurring gains and losses, will be -289 million yuan for the year 2024

### Related Stocks

- [600076.CN](https://longbridge.com/en/quote/600076.CN.md)

## Related News & Research

- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [Cocoa Prices Fall on Rising Nigerian Cocoa Exports](https://longbridge.com/en/news/296637826.md)
- [CDC lifts beneficial stake in Exosens to 11.71% of capital, 13.87% of voting rights](https://longbridge.com/en/news/296499698.md)
- [Zaptec insider-linked company buys shares worth NOK 12.36 million](https://longbridge.com/en/news/296378460.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**